Health
As RFK Jr. Champions Chronic Disease Prevention, Key Research Is Cut
Robert F. Kennedy Jr. has spoken of an “existential threat” that he said can destroy the nation.
“We have the highest chronic disease burden of any country in the world,” Mr. Kennedy said at a hearing in January before the Senate confirmed him as the secretary of Health and Human Services.
And on Monday he is starting a tour in the Southwest to promote a program to combat chronic illness, emphasizing nutrition and lifestyle.
But since Mr. Kennedy assumed his post, key grants and contracts that directly address these diseases, including obesity, diabetes and dementia, which experts agree are among the nation’s leading health problems, are being eliminated.
These programs range in scale and expense. Researchers warn that their demise could mean lost opportunities to address an aspect of public health that Mr. Kennedy has said is his priority.
“This is a huge mistake,” said Dr. Ezekiel Emanuel, the co-director of the Healthcare Transformation Institute at the University of Pennsylvania’s Perelman School of Medicine.
Decades of Diabetes Research Discontinued
Ever since its start in 1996, the Diabetes Prevention Program has helped doctors understand this deadly chronic disease. The condition is the nation’s most expensive, affecting 38 million Americans and incurring $306 billion in one recent year in direct costs. With about 400,000 deaths in 2021, it was the eighth leading cause of death.
The program has been terminated, and the reason has little to do with its merits. Instead, it seems to be a matter of a lead researcher’s working in the wrong place at the wrong time.
The program began when doctors at 27 medical centers received funding from the National Institutes of Health for a study asking whether Type 2 diabetes could be prevented. The 3,234 participants had high risk of the disease.
The results were a huge victory. Those assigned to follow a healthy diet and exercise routine regularly reduced their chances of developing diabetes by 58 percent. Those who took metformin, a drug that lowers blood sugar, decreased their risk by 31 percent.
The program entered a new phase, led by Dr. David M. Nathan, a diabetes expert at Harvard Medical School. Researchers followed the participants to see how they fared without the constant attention and support of a clinical trial. The researchers also examined their genetics and metabolism and looked at measures of frailty and cognitive function.
Several years ago, the investigators had an idea. Some studies suggested that people with diabetes had a higher risk of dementia. But scientists didn’t know if it was vascular dementia or Alzheimer’s or what the precise risk factors were. The diabetes program could renew its focus on investigating this with its 1,700 aging participants.
The group added a new principal investigator, the dementia expert Dr. Jose A. Luchsinger. For administrative reasons, including the newfound focus on dementia, the program decided its money should flow through Dr. Luchsinger’s home institution, Columbia University, rather than through Harvard or George Washington University, where a third principal investigator works.
On March 7, the Trump administration cut $400 million in grants and contracts to Columbia, saying Jewish students were not protected from harassment during protests over the war in Gaza. The diabetes grant was among those terminated: $16 million a year that Columbia shared across 30 medical centers. The study ended abruptly.
Asked about the termination, Andrew G. Nixon, director of communications at the Department of Health and Human Services, provided a statement from the agency’s acting general counsel saying that “anti-Semitism is clearly inconsistent with the fundamental values that should inform liberal education” and that “Columbia University’s complacency is unacceptable.”
At the time their grant ended, the researchers had started advanced cognitive testing for evidence of dementia in patients, followed by brain imaging to look for amyloid, the hallmark of Alzheimer’s disease. They planned to complete the tests during the next two years.
Then, Dr. Luchsinger said, the group was going to look at blood biomarkers of amyloid and other signs of dementia, including brain inflammation. For comparison, they planned to perform the same tests on participants’ blood samples from 7 and 15 years ago.
“Very few studies have blood collected and stored going that far back,” Dr. Luchsinger said.
Now much of the work cannot begin, and the part that had started remains incomplete.
Another troubling question the researchers hoped to answer was whether metformin increases, decreases or has no effect on the risk of dementia.
“This is the largest and longest study of metformin ever,” Dr. Luchsinger said. Participants assigned to take the drug in the 1990s took it for more than 20 years.
“We thought we had the potential to put to rest this question about metformin,” Dr. Luchsinger said.
The only ways to save the program, Dr. Nathan said, are for Mr. Kennedy to agree to restore the funding at Columbia or to transfer the grant to a principal investigator at another medical center.
The study investigators are appealing to the diabetes caucus in Congress, hoping it can help make their case to the Health and Human Services.
“We hope the congressmen and senators might prevail and say: ‘This is crazy. This is chronic disease. This is what you wanted to study,’” Dr. Nathan said.
So far, there has been no change.
Include Diversity. Actually, That’s Too Much Diversity.
Compared with the Diabetes Prevention Program, a program to train pediatricians to become scientists is tiny. But pediatric researchers say that the Pediatric Scientist Development Program helps ensure that chronic childhood diseases are included in medical research.
It began 40 years ago when chairs of pediatric departments called for the creation of the program, which has been continually funded ever since by the National Institute of Child Health and Human Development.
Participants are clinicians who were trained in subspecialties like endocrinology and nephrology, practiced as clinicians and were inspired to go into research to help young patients with the diseases they had seen firsthand.
The highly competitive program pays for seven to eight pediatricians to train at university medical centers for a year, pairing them with mentors and giving them time away from the clinic to research conditions including obesity, asthma and chronic kidney disease.
In retrospect, the program’s fate was sealed in 2021 when its leaders applied for a renewal of their grant. It seemed pro forma. This was its eighth renewal.
This time, though, an external committee of grant reviewers told the investigators their proposal’s biggest weakness was a lack of diversity. The program needed to seek pediatricians who represented diverse ethnicities, economic backgrounds, states, types of research and pediatric specialties.
The critique said, for example, that “attention must be given to recruiting applicants from diverse backgrounds, including from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences.”
So the program’s leaders sprinkled diversity liberally through a rewritten grant application.
“Diversity, in its broadest sense, was all over the grant,” said Dr. Sallie Permar, professor and chairwoman of pediatrics at Weill Cornell Medical College and director of the program. “It was exactly what the reviewers appreciated when we resubmitted.”
The grant was renewed in 2023. Now it is terminated. The reason? Diversity.
The termination letter, from officials in the National Institute of Child Health and Human Development, said there was no point in trying to rewrite the grant request. The inclusion of diversity made the application so out of line that “no modification of the project could align the project with agency priorities.”
Mr. Nixon, the health department spokesman, did not reply to queries about the pediatric program’s cancellation.
Participants in the program are distraught.
Dr. Sean Michael Cullen had been studying childhood obesity at Weill Cornell in New York. He has investigated why male mice fed a high-fat diet produced offspring that became fat, even when those offspring were fed a standard diet.
He hoped his findings would help predict in humans which children were at risk of obesity so pediatricians could try to intervene.
Now the funds are gone. He may seek private or philanthropic funding, but he doesn’t have any clear prospects.
Dr. Evan Rajadhyaksha is in a similar situation. He’s a childhood kidney disease specialist at Indiana University. When he was a resident, he cared for a little girl who developed kidney disease because of a condition in which some urine washes up from the bladder into the kidneys.
Dr. Rajadhyaksha has a hypothesis that vitamin D supplementation could protect children with this condition.
Now, that work has to stop. Without funding, he expects to leave research and return to clinical work.
Dr. Permar said she hadn’t given up. The program costs only $1.5 million each year, so she and her colleagues are looking for other support.
“We are asking foundations,” she said. “We are starting to ask industry — we haven’t had industry funding before. We are asking department chairs and children’s hospitals, are they willing to fund-raise?”
“We are literally looking under every couch cushion,” Dr. Permar said.
“But,” she said, federal support for the program “has been the foundation and cannot be supplanted.”
NEWYou can now listen to Fox News articles!
Washington, DC – Medical victim Chloe Cole was at the center of the U.S. Department of Health and Human Services’ Thursday announcement of proposed regulatory actions to end “sex-rejecting procedures” on minors.
The proposed regulatory actions by the HHS are part of President Donald Trump‘s January executive order calling on the department to protect children from “chemical and surgical mutilation.”
The department is rolling out a series of policy updates and regulatory actions that would effectively defund hospitals that provide gender transition procedures, according to an HHS official.
NUMBER OF YOUNG ADULTS IDENTIFYING AS TRANSGENDER PLUNGES BY NEARLY HALF IN TWO YEARS
Cole, now 21 years old, went through the process of medical transition from female to male between the ages of 12 and 16.
The California native took to the stage alongside HHS Secretary Robert F. Kennedy Jr. and other officials Thursday to advocate for the protection of children. Afterward, she told Fox News Digital the puberty blockers, testosterone injections and double mastectomy she endured have irreversibly and permanently affected her health.
Detransitioner Chloe Cole joined HHS Secretary Robert F. Kennedy Jr. on Thursday as he announced proposed regulations ending gender treatments for children. (Fox News Digital)
“As soon as gender was in the picture, none of my doctors or psychologists asked the real questions that they should have,” said Cole. “The entire focus was on my feelings and what I wanted rather than what I really needed in that moment.”
What she needed, Cole said, was to be loved and affirmed for the way God created her — “as a young and yet tomboyish little girl.”
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
She maintained that her doctors neglected to share risks, only touting the “benefits” of stopping female puberty and using testosterone to promote body hair growth, musculature and different fat distribution.
“There was nothing they could say to me that would make me understand the gravity of what I was about to go through, because I was still growing up,” said Cole. “I had very little experience in the world, and I simply would not be mature enough to be equipped to undergo such a life-changing procedure in every way.”
“I had very little experience in the world, and I simply would not be mature enough to be equipped to undergo such a life-changing procedure in every way,” Cole, pictured above in both pictures, told Fox News Digital. (Chloe Cole; Fox News Digital)
Cole noted that her parents never thought she was transgender, but felt like the odds were stacked against them.
“At the time when we started going through this as a family, there really were no resources that would speak to the reality of transgenderism, especially for children,” she said. “Most people were not aware then that this was something that was even happening in our hospital systems.”
CLICK HERE FOR MORE HEALTH STORIES
Cole said her parents were warned that if they did not allow her to transition, she would likely commit suicide.
“My legal guardians were forced to make this decision under duress,” she shared in a previous statement. “But even if my parents had supported transitioning medically from the start, no parent or any adult, ultimately, has a right to determine whether a child gets to be chemically sterilized or mutilated.”
“While there are only two sexes, there’s a million different ways that you can be yourself,” said Cole, pictured above during her surgeries. (Chloe Cole)
Cole said she’s suffered numerous complications from her medications and surgery. “My quality of life is still being impacted to this day,” she wrote in her statement.
Her fertility status now remains unknown, she said. She will not be able to breastfeed because her breasts were surgically removed.
“As an adult, I am now grieving, and on top of that, the areolar skin grafts they used in my surgery began to fail two years afterward. I must wear bandages on my chest every day,” Cole wrote.
“As an adult, I am now grieving.”
In 2023, Cole filed a lawsuit with the Center for American Liberty (CAL) against hospitals for pushing her into what she believes is medical mutilation.
Mark Trammell of CAL told Fox News Digital that Thursday’s HHS announcement “represents a critical acknowledgment that experimental medical interventions on children with gender distress have failed to meet basic standards of safety and effectiveness.”
Cole, who detransitioned after medical procedures, is warning others to wait and seek family support before transitioning. (Fox News Digital)
“It signals that medicine must return to its core ethical obligation: First, do no harm,” Trammell added.
“We will continue fighting to ensure accountability for the institutions that promoted these practices and to secure justice for the children and detransitioners whose lives were forever altered.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
In a previous statement provided to Fox News Digital, Dr. Marc Siegel, Fox News senior medical analyst, said he is in favor of a “more conservative approach” for minors.
“Long-term effects of puberty blockers may include bone loss, trouble concentrating, interference with learning and interference with fertility,” he said. “I think it makes sense in most cases to treat underlying mental health concerns before jumping into treatments, including surgery, that may be difficult to reverse.”
“It makes sense in most cases to treat underlying mental health concerns before jumping into treatments.”
The doctor also emphasized that gender issues should not be overly politicized. “This means not superimposing an ideology or pushing physicians to act in a certain way or under pressure,” Siegel said.
Cole began the gender transition process at age 12 and received a double mastectomy surgery at 15 years old. (Fox News Digital)
“The welfare of the child must come first. In this case, it means going very slowly and providing support to a child or teen with gender dysphoria.”
Cole shared that she hopes any children who are questioning whether they should transition wait.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“While there are only two sexes, there are a million different ways that you can be yourself,” she added.
“God is there for you. He is the one who has created you this way, and you can seek his counsel,” Cole went on.
“You can continue praying, and I think ultimately it’s connecting with your family, building your purpose in this world, and looking to the gospel and up to God.”
Fox News Digital’s Emma Colton contributed reporting.
NEWYou can now listen to Fox News articles!
Those at risk of type 2 diabetes may be able to prevent heart problems later.
A new study published in The Lancet Diabetes & Endocrinology discovered that lowering the blood sugar of those with prediabetes could reduce the risk of heart attack by half.
Diabetes researchers and endocrine experts across Europe, China and the U.S. investigated how bringing blood sugar back to normal levels affected the chances of heart problems later in life, based on a 20-year American study and a 30-year Chinese study, according to a press release.
CLICK HERE FOR MORE HEALTH STORIES
In both studies, the prediabetic participants were coached to make appropriate lifestyle changes to lower blood sugar (the amount of glucose in the bloodstream) through diet and exercise, also targeting weight loss.
Participants worked to lower blood sugar through diet and exercise targeted at weight loss. (iStock)
The researchers split the participants into a remission group (where blood sugar returned to normal) and a non-remission group, which included those still in the prediabetes range. They then determined who in these groups had died from heart disease or were hospitalized for heart failure.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Participants who went into remission had a 58% lower risk of dying from heart disease and being hospitalized for heart failure. This group also had a lower risk of other major heart events and lower overall death rates.
These heart-protective benefits lasted for decades after the program ended, the researchers found.
Those in prediabetes remission had their risk of a heart event reduced by more than half. (iStock)
“Reaching prediabetes remission is linked to a decades-long benefit, halving the risk of cardiovascular death or hospitalization for heart failure in diverse populations,” the researchers commented in the publication of the study. “Targeting remission might represent a new approach to cardiovascular prevention.”
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
In an interview with Fox News Digital, Dr. Andreas Birkenfeld, study co-author and professor of medicine at the University Hospital Tübingen in Germany, reiterated that reaching prediabetes remission is not only relevant for reducing the progression of type 2 diabetes, but may also be associated with a “meaningful reduction in… heart attack risk, cardiac death and heart failure.”
“Importantly, this underscores that prediabetes is a modifiable stage where timely, evidence-based interventions (especially lifestyle measures, and in selected cases, medication) can make a real difference,” he added.
“Reaching prediabetes remission is linked to a decades-long benefit, halving the risk of cardiovascular death or hospitalization for heart failure in diverse populations,” the researchers commented. (iStock)
The study did have some limitations, including that it is based on analysis of trials not originally designed to measure cardiovascular outcomes, which means the results show association but cannot prove causation.
In addition, unmeasured lifestyle and health factors, population differences and lack of randomization for heart outcomes may have influenced the reduced cardiovascular risk, the researchers acknowledged.
“This underscores that prediabetes is a modifiable stage where timely, evidence-based interventions … can make a real difference.”
Birkenfeld suggested that those with prediabetes should ask their doctors the following questions: “What is my current status? What is my personal cardiovascular risk? What is my target blood glucose level?”
Patients should also inquire about the frequency of testing for blood sugar and key risk factors like blood pressure, cholesterol and other related conditions, such as kidney function or sleep apnea, he advised.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“If lifestyle changes aren’t enough or my risk is high, would medication be appropriate for me — and what are the benefits and downsides?” the researcher asked as an example.
About 98 million American adults, more than one in three, have prediabetes, according to CDC data. Eight in 10 of these adults are unaware that they have the disease.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
Video: Fans in Tokyo Visit Twin Pandas Before They Head to China
Video: Trump Mocks Obama, Biden in His Presidential ‘Walk of Fame’
Video: President Trump Reclassifies Marijuana With Executive Order
Video: 250 Years of Jane Austen, in Objects
President Trump to add his own name to the Kennedy Center
Florida High School Football Rankings: Top 25 teams – Oct. 21
Cleary's 21 help Le Moyne down Central Connecticut State 69-64 in OT
How old is Bo Nix? What to know about Oregon quarterback ahead of 2024 NFL Draft
99th annual Pony Swim held in Virginia
Video: ‘It Didn’t Have to Happen This Way:’ U.Va. Faculty Call for Review of Police Response to Protests
Video: Trump Mocks Obama, Biden in His Presidential ‘Walk of Fame’
Trump quietly signs sweeping $901B defense bill after bipartisan Senate passage
Mercosur signature delayed to January after Meloni asks for more time
Is ISIS making a comeback? : Sources & Methods
Texas Republicans launch ‘Sharia Free America Caucus’ aimed at defending ‘Western civilization’
-
Iowa4 days agoAddy Brown motivated to step up in Audi Crooks’ absence vs. UNI
-
Washington1 week agoLIVE UPDATES: Mudslide, road closures across Western Washington
-
Iowa5 days agoHow much snow did Iowa get? See Iowa’s latest snowfall totals
-
Maine2 days agoElementary-aged student killed in school bus crash in southern Maine
-
Maryland4 days agoFrigid temperatures to start the week in Maryland
-
Technology1 week agoThe Game Awards are losing their luster
-
South Dakota4 days agoNature: Snow in South Dakota
-
Nebraska1 week agoNebraska lands commitment from DL Jayden Travers adding to early Top 5 recruiting class